383 related articles for article (PubMed ID: 1323093)
21. Activity of clarithromycin against Mycobacterium avium complex infection in beige mice.
Klemens SP; DeStefano MS; Cynamon MH
Antimicrob Agents Chemother; 1992 Nov; 36(11):2413-7. PubMed ID: 1336945
[TBL] [Abstract][Full Text] [Related]
22. In-vitro synergistic activity between ethambutol and fluorinated quinolones against Mycobacterium avium complex.
Hoffner SE; Kratz M; Olsson-Liljequist B; Svenson SB; Källenius G
J Antimicrob Chemother; 1989 Sep; 24(3):317-24. PubMed ID: 2808189
[TBL] [Abstract][Full Text] [Related]
23. [A new, highly synergistic drug combination for the treatment of infections with multiresistant mycobacteria, especially the mycobacterium avium complex].
Seydel JK; Schaper KJ
Immun Infekt; 1992 Apr; 20(2):46-9. PubMed ID: 1377169
[TBL] [Abstract][Full Text] [Related]
24. In vitro, ex-vivo and in vivo activities of ethambutol and sparfloxacin alone and in combination against mycobacteria.
Kaur D; Khuller GK
Int J Antimicrob Agents; 2001 Jan; 17(1):51-5. PubMed ID: 11137649
[TBL] [Abstract][Full Text] [Related]
25. Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages.
Perronne C; Gikas A; Truffot-Pernot C; Grosset J; Pocidalo JJ; Vilde JL
Antimicrob Agents Chemother; 1990 Aug; 34(8):1508-11. PubMed ID: 2171421
[TBL] [Abstract][Full Text] [Related]
26. [Utility of the direct culture examination (Ziehl-Neelsen) using the Bactec system for the presumptive identification of Mycobacterium tuberculosis complex, Mycobacterium avium complex, Mycobacterium xenopi, and Mycobacterium kansasii].
Moreno C; Garrigó M; Sánchez F; Coll P
Enferm Infecc Microbiol Clin; 1994 May; 12(5):241-5. PubMed ID: 7811323
[TBL] [Abstract][Full Text] [Related]
27. Does in vitro susceptibility to rifabutin and ethambutol predict the response to treatment of Mycobacterium avium complex bacteremia with rifabutin, ethambutol, and clarithromycin? Canadian HIV Trials Network Protocol 010 Study Group.
Shafran SD; Talbot JA; Chomyc S; Davison E; Singer J; Phillips P; Salit I; Walmsley SL; Fong IW; Gill MJ; Rachlis AR; Lalonde RG
Clin Infect Dis; 1998 Dec; 27(6):1401-5. PubMed ID: 9868650
[TBL] [Abstract][Full Text] [Related]
28. Disseminated Mycobacterium avium complex infection.
Inderlied CB; Kemper CA
AIDS Clin Rev; 1992; ():131-72. PubMed ID: 1606056
[No Abstract] [Full Text] [Related]
29. Differences in drug susceptibility pattern between Mycobacterium avium and Mycobacterium intracellulare isolated in respiratory specimens.
Cho EH; Huh HJ; Song DJ; Moon SM; Lee SH; Shin SY; Kim CK; Ki CS; Koh WJ; Lee NY
J Infect Chemother; 2018 Apr; 24(4):315-318. PubMed ID: 29223615
[TBL] [Abstract][Full Text] [Related]
30. Synergistic activity of rifampicin and ethambutol against slow-growing nontuberculous mycobacteria is currently of questionable clinical significance.
van Ingen J; Hoefsloot W; Mouton JW; Boeree MJ; van Soolingen D
Int J Antimicrob Agents; 2013 Jul; 42(1):80-2. PubMed ID: 23664674
[TBL] [Abstract][Full Text] [Related]
31. Rifabutin in combination with clofazimine, isoniazid and ethambutol in the treatment of AIDS patients with infections due to opportunist mycobacteria. Groupe d'Etude et de Traitement des Infections à Mycobacteries Résistantes.
Dautzenberg B; Truffot C; Mignon A; Rozenbaum W; Katlama C; Perronne C; Parrot R; Grosset J
Tubercle; 1991 Sep; 72(3):168-75. PubMed ID: 1663282
[TBL] [Abstract][Full Text] [Related]
32. [Susceptibility to rifabutin and novel fluoroquinolones in Mycobacterium avium complex isolates from patients with sputum culture-positive pulmonary disease who are undergoing standard chemotherapy].
Tateishi Y; Motone M; Yoshimura K; Miki M; Miki K; Kitada S; Hashimoto H; Hiraga T; Maekura R
Nihon Kokyuki Gakkai Zasshi; 2010 Nov; 48(11):797-802. PubMed ID: 21141056
[TBL] [Abstract][Full Text] [Related]
33. Drug susceptibility testing and pharmacokinetics question current treatment regimens in Mycobacterium simiae complex disease.
van Ingen J; Totten SE; Heifets LB; Boeree MJ; Daley CL
Int J Antimicrob Agents; 2012 Feb; 39(2):173-6. PubMed ID: 22099521
[TBL] [Abstract][Full Text] [Related]
34. In vitro activity of antimicrobial agents against the Mycobacterium avium complex inside macrophages from HIV1-infected individuals: the link to clinical response to treatment?
Yajko DM
Res Microbiol; 1992 May; 143(4):411-9. PubMed ID: 1455069
[No Abstract] [Full Text] [Related]
35. Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial.
Dautzenberg B; Truffot C; Legris S; Meyohas MC; Berlie HC; Mercat A; Chevret S; Grosset J
Am Rev Respir Dis; 1991 Sep; 144(3 Pt 1):564-9. PubMed ID: 1832527
[TBL] [Abstract][Full Text] [Related]
36. Activity of rifabutin alone and in combination with clofazimine, kanamycin and ethambutol against Mycobacterium intracellulare infections in mice.
Saito H; Sato K
Tubercle; 1989 Sep; 70(3):201-5. PubMed ID: 2559522
[TBL] [Abstract][Full Text] [Related]
37. Combinations of rifampin or rifabutine plus ethambutol against Mycobacterium avium complex. Bactericidal synergistic, and bacteriostatic additive or synergistic effects.
Heifets LB; Iseman MD; Lindholm-Levy PJ
Am Rev Respir Dis; 1988 Mar; 137(3):711-5. PubMed ID: 2830814
[TBL] [Abstract][Full Text] [Related]
38. In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.
Kohno Y; Ohno H; Miyazaki Y; Higashiyama Y; Yanagihara K; Hirakata Y; Fukushima K; Kohno S
Antimicrob Agents Chemother; 2007 Nov; 51(11):4071-6. PubMed ID: 17709469
[TBL] [Abstract][Full Text] [Related]
39. Prospects for development of new antimycobacterial drugs, with special reference to a new benzoxazinorifamycin, KRM-1648.
Tomioka H
Arch Immunol Ther Exp (Warsz); 2000; 48(3):183-8. PubMed ID: 10912623
[TBL] [Abstract][Full Text] [Related]
40. [Radiometric determination of Mycobacterium avium-intracellulare and Mycobacterium xenopi sensitivity to antitubercular agents].
Kubín M; Lindholm-Levy P; Heifets LB
Epidemiol Mikrobiol Imunol; 1994 Sep; 43(3):104-6. PubMed ID: 7953081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
